Colorectal Cancer

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the utility of aflibercept in patients with advanced colorectal cancer.

Josep Tabernero, MD, PhD, of Vall d'Hebron University Hospital, Barcelona, discusses new characterizations of colorectal cancer.

Paul Ruff, MD, director of Medical Oncology at the University of Witwatersrand, Johannesburg, South Africa, discusses treating elderly patients with colorectal cancer with aflibercept.

The American Cancer Society estimates that in 2013, 142,820 individuals in the United States will be diagnosed with colorectal cancer and 72,570 with bladder cancer

Paul Ruff, MD, director of medical oncology at the University of Witwatersrand, Johannesburg, South Africa, discusses the analysis of prior bevacizumab in the VELOUR trial in patients with metastatic colorectal cancer.

Takayuki Yoshino, MD, medical oncologist, National Cancer Center Hospital East, Chiba, Japan, discusses U3-1565 and TAS-102, two agents used to treat colorectal cancer.

Panitumumab proved noninferior to cetuximab in extending overall survival in patients with chemorefractory KRAS wild-type metastatic colorectal cancer.

Edith Mitchell, MD, FACP, clinical professor, director, Center to Eliminate Cancer Disparities Program Leader, Thomas Jefferson University, discusses an analysis of the VELOUR trial.